NCT03432598 - Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 24, 2017

Primary Completion Date

February 25, 2019

Study Completion Date

December 21, 2020

Conditions

Locally Advanced Lung Cancer; Metastatic Lung Cancer

Interventions

DRUG

Tislelizumab

Administered 200 mg intravenously (IV) as specified in the treatment arm

DRUG

Paclitaxel

Administered 175 mg/m² IV as specified in the treatment arm

DRUG

Gemcitabine

Administered 1250 mg/m² IV as specified in the treatment arm

DRUG

Etoposide

Administered 100 mg/m2 IV as specified in the treatment arm

DRUG

Pemetrexed

Administered 500 mg/m² IV as specified in the treatment arm

DRUG

Cisplatin

Administered 75 mg/m²/day IV as specified in the treatment arm

DRUG

Carboplatin

Administered AUC 5 as specified in the treatment arm

Trial Locations (7)

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

Beijing Cancer Hospital, Beijing

Beijing Chest Hospital, Capital Medical University, Beijing

Jilin Cancer Hospital, Changchun

The First Hospital of Jilin University, Changchun

Jiangsu Province Hospital, Nanjing

Henan Cancer Hospital, Zhengzhou